Atwood & Palmer’s Clovis Oncology, Inc. CLVS Stock Holding History

Atwood & Palmer’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$2K	–	341
2019 Q1	$2K	Hold	100	–	–	﹤0.01%	314
2018 Q4	$2K	Hold	100	–	–	﹤0.01%	305
2018 Q3	$3K	Hold	100	–	–	﹤0.01%	297
2018 Q2	$5K	Hold	100	–	–	﹤0.01%	277
2018 Q1	$5K	Hold	100	–	–	﹤0.01%	270
2017 Q4	$7K	Hold	100	–	–	﹤0.01%	260
2017 Q3	$8K	Hold	100	–	–	﹤0.01%	262
2017 Q2	$9K	Hold	100	–	–	﹤0.01%	261
2017 Q1	$6K	Hold	100	–	–	﹤0.01%	261
2016 Q4	$4K	Hold	100	–	–	﹤0.01%	299
2016 Q3	$4K	Hold	100	–	–	﹤0.01%	296
2016 Q2	$1K	Hold	100	–	–	﹤0.01%	304
2016 Q1	$2K	Hold	100	–	–	﹤0.01%	302
2015 Q4	$4K	Hold	100	–	–	﹤0.01%	368
2015 Q3	$9K	Sell	100 -200	-67%	-$17.3K	﹤0.01%	345
2015 Q2	$26K	Buy	+300	New	+$25.7K	﹤0.01%	228

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Atwood & Palmer's CLVS Position: Q2 2019 in Review

Atwood & Palmer sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 100 shares — an estimated $2K sold.

Atwood & Palmer first reported a position in CLVS in Q2 2015 and held it in 16 quarters. The position peaked at $26K in Q2 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

Atwood & Palmer reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
Atwood & Palmer sold 100 Clovis Oncology, Inc. shares in Q2 2019, an estimated $2K.
Atwood & Palmer first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 16 quarters.
Atwood & Palmer's Clovis Oncology, Inc. position peaked at $26K in Q2 2015.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Atwood & Palmer's 13F filing for Q2 2019, filed 17 Jul 2019.